US Patent

US11185535 — Amorphous kinase inhibitor formulations and methods of use thereof

Formulation · Assigned to Deciphera Pharmaceuticals LLC · Expires 2040-12-30 · 15y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects amorphous formulations of a kinase inhibitor compound useful in treating disorders related to the activity of certain kinases.

USPTO Abstract

Provided herein is an amorphous compound represented by Formula (I):and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US11185535
Jurisdiction
US
Classification
Formulation
Expires
2040-12-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Deciphera Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.